Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload (HYPERION)
This study is ongoing, but not recruiting participants.
Study NCT01254227   Information provided by Novartis

First Received on September 21, 2010.   Last Updated on July 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiac Iron Overload
Additional conditions recognized in this trial
Iron Overload
More general conditions related to this trial
Iron Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
Deferasirox and Deferoxamine
Additional drug interventions recognized in this trial
Deferasirox
Deferoxamine
More general drug interventions related to this trial
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Siderophores
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services